Compare Novo Nordisk A/S (NVO) vs Nasdaq100 ETF (QQQ) Price & Performance

Novo Nordisk A/STrade

Nasdaq100 ETFTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Nasdaq100 ETF — how do they compare? Novo Nordisk A/S trades at $45.01 (market cap $198.57B), while Nasdaq100 ETF trades at $713.68. The key difference: Novo Nordisk A/S pays a 4.03% dividend while Nasdaq100 ETF pays none, and Nasdaq100 ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.

	NVO	QQQ
Market Cap	$198.57B	—
Sector	Health	—
52-Week High	$63.98	$746.16
52-Week Low	$35.29	$558.34
Enterprise Value	$213.37B	—
Dividend Yield	4.03%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.

The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.

Nasdaq100 ETF

QQQ trades at $718.36, down slightly by 0.08% on the day, with a bullish technical outlook from moving averages and neutral oscillators. Support levels are at $715 and $712, with resistance at $722 and $725. Analyst sentiment is split evenly between buy and sell recommendations, reflecting uncertainty amid mixed news coverage.

The ETF's outlook is supported by strong historical performance and growth exposure, but risks include fee competitiveness and market volatility. Investors should weigh the divided analyst consensus against the fund's track record in technology and growth sectors.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Canada imposes retaliatory tariffs on $20B of U.S. goods, escalating trade tensions and impacting North American supply chains.Seeking Alpha · 2 days agoNeutral 4-Factor Dividend Growth Strategy slightly outperforms SCHD with 14.89% returns, testing new variants.Seeking Alpha · 3 days agoBullish View details →

QQQ

S&P 500 dividend yield near 1%, buybacks and retained earnings now key for shareholder returnsSeeking Alpha · 4 hours agoNeutral TQQQ returned 59.18% vs. QQQ's 24.99%, but leverage costs and daily resets reduce its triple return over time.24/7 Wall Street · 17 hours agoNeutral iShares Future AI & Tech ETF gains 78.2% in 12 months but carries high risk due to sector concentration and weak holdings.Seeking Alpha · 22 hours agoNeutral View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About Nasdaq100 ETF

The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.